| Description |
1 online resource |
| Contents |
Front Cover; Materials and Devices for Bone Disorders; Copyright Page; Contents; List of Contributors; Biography; Preface; 1 Introduction to Biomaterials and Devices for Bone Disorders; 1.1 Introduction; 1.2 Metallic Biomaterials; 1.3 Ceramic Biomaterials; 1.4 Polymeric Biomaterials; 1.5 Composite Biomaterials; 1.6 Additive Manufacturing (AM) of Biomaterials; 1.7 Biomaterials in Orthopedic Implants Devices; 1.7.1 Joint replacements; 1.7.2 Implants used in osteosynthesis for stabilization and fracture repair; 1.7.3 Spine implants; 1.7.4 Nonconventional implants for bone tumor |
|
1.7.5 Multifunctional devices1.8 Summary and Future Directions; Acknowledgments; References; 2 Bone Biology and Effects of Pharmaceutical Intervention on Bone Quality; 2.1 Bone Biology; 2.1.1 Bone functions; 2.1.2 Composition; 2.1.3 Architecture; 2.1.4 Bone cells; 2.1.4.1 Osteoclasts; 2.1.4.2 Osteoblast lineage; 2.1.4.2.1 The Wnt-signaling system; 2.1.4.3 Preosteoblasts; 2.1.4.4 Reversal cells; 2.1.4.5 Mature osteoblasts; 2.1.4.6 Lining cells; 2.1.4.7 Osteocytes; 2.1.5 Bone remodeling; 2.1.5.1 The basic multicellular unit; 2.1.5.2 Sequence of bone remodeling; 2.1.5.2.1 Origination |
|
2.1.5.2.2 Activation2.1.5.2.3 Resorption; 2.1.5.2.4 Reversal; 2.1.5.2.5 Formation; 2.1.5.2.6 Mineralization; 2.1.5.2.7 Reestablishing osteocyte network; 2.1.5.2.8 Quiescence; 2.1.6 Fracture repair; 2.1.6.1 Stress fractures; 2.1.6.2 Complete fractures; 2.1.7 Aspects of bone strength; 2.1.7.1 Bone shape; 2.1.7.2 Bone volume; 2.1.7.3 Mineralization density; 2.1.7.4 Microarchitecture; 2.1.7.5 Collagen structure; 2.1.7.6 Ability to repair damage; 2.1.7.7 Crystal characteristics; 2.1.7.8 Bone marrow; 2.1.7.9 Overall bone strength; 2.2 Pharmaceutical Intervention |
|
2.2.1 Bone loss with aging or disease2.2.2 Actions of systemic hormones and local cytokines; 2.2.2.1 Estrogen; 2.2.2.2 Glucocorticosteroids; 2.2.2.3 Thyroid; 2.2.2.4 Parathyroid; 2.2.2.5 Calcitonin; 2.2.2.6 1,25 (OH)2-Cholecalciferol (1,25D); 2.2.2.7 Insulin and insulin-like growth factor; 2.2.2.8 Serotonin; 2.2.2.9 Local cytokines; 2.2.3 Calcium supplementation; 2.2.4 Bone formation with osteoporosis medications; 2.2.5 Raloxifene; 2.2.6 Bisphosphonates; 2.2.6.1 Short-term effects; 2.2.6.2 Long-term effects; 2.2.6.3 Fracture healing; 2.2.7 Denosumab; 2.2.8 Teriparatide; 2.2.9 Strontium |
|
2.2.10 Emerging therapies2.2.10.1 Cathepsin K inhibitors; 2.2.10.2 Romosozumab; 2.2.11 Other medications or substances that affect bone strength; 2.2.11.1 Anticonvulsants; 2.2.11.2 Selective serotonin reuptake inhibitors; 2.2.11.3 Carbonic anhydrase inhibitors; 2.2.11.4 Thiazide diuretics; 2.2.11.5 Rosiglitazone; 2.2.11.6 Bortezomib; 2.2.11.7 Lithium; 2.2.11.8 Elements toxic to the bone; 2.2.11.9 Fluoride; 2.3 Summary; References; 3 Bone Disorders; 3.1 Introduction; 3.2 Metabolic Diseases; 3.2.1 Osteoporosis; 3.2.2 Paget's disease; 3.3 Degenerative Disc Disease; 3.4 Osteoarthritis |
| Notes |
Online resource; title from digital title page (viewed on October 26, 2018) |
| Subject |
Bones -- Mechanical properties.
|
|
Bones -- Diseases -- Treatment
|
|
MEDICAL -- Surgery -- General.
|
|
Bones -- Diseases -- Treatment
|
|
Bones -- Mechanical properties
|
| Form |
Electronic book
|
| Author |
Bose, Susmita, editor.
|
|
Bandyopadhyay, Amit, 1967- editor.
|
| ISBN |
9780128028032 |
|
0128028033 |
|
